News

Technology News

Bard Acquires Lutonix For Angioplasty Balloon

Wednesday, December 21, 2011 5:01:00 AM PDT | VentureDeal Staff
   Murray Hill, New Jersey  -- C. R. Bard (NYSE: BCR) announced that it has acquired medical device maker Lutonix.

Lutonix is conducting an investigational device exemption (IDE) trial for using drug-coated balloons for the treatment of peripheral arterial disease.




The company says that the market for drug-coated balloons could "approach $1 billion annually over the next decade."

Bard paid approximately $225 million at closing, with a milestone payment of an additional $100 million upon PMA approval of Lutonix' balloon device.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1